A n Kang is a Chinese pharmaceutical entrepreneur who is the chairman of Hualan Biological Engineering, a leading manufacturer of vaccines and blood products in China. He has built his career and fortune by capitalizing on the growing demand for healthcare products in the world's most populous country. He has a background in medicine and has held positions at various healthcare institutions before venturing into business.

Hualan Biological Engineering has become a major player in the Chinese biopharmaceutical industry. The company is a key producer of seasonal flu vaccines and was one of the first to develop a vaccine for the H1N1 influenza strain. A significant part of its business is also in plasma-derived products, such as albumin and immunoglobulin, which are essential for treating a variety of medical conditions. An Kang's leadership has positioned the company as a critical component of China's public health infrastructure.